



Press Release

International Meeting on Antimicrobial Peptides in Leipzig sponsored by AMP Therapeutics

Leipzig (Germany), August 25, 2012 – FOR IMMEDIATE RELEASE

The International Meeting on Antimicrobial Peptides (IMAP) took place from August 30-31 2012. For the meeting more than 100 international scientists gathered at the University of Leipzig, Center for Biotechnology and Biomedicine, which hosted the meeting for the second time.

In several plenary sessions and keynote lectures the emphasis lay on state-of-the-art research in antimicrobial peptides (AMPs) from natural origin. The oral and poster presentations were focused on specific AMPs such as apidaecins, cathelicidins and cyclotides including their potential application to support the pharmaceutical development of urgently needed new antibiotics for multi-resistant bacterial infections. The meeting's program can be viewed under www.uni-leipzig.de/~bioanaly/IMAP2012.

Dr. Marc W. Hentz, Managing Director at AMP Therapeutics GmbH responsible for Business Development and Finances commented: "It is a great success for Leipzig as a research cluster to have again attracted this prestigious event. We were happy to collaborate with the organizers in enabling this symposium."

Dr. Knut Adermann, Managing Director at AMP Therapeutics GmbH responsible for Research and Development further added: "Together with the Central German Symposium on Infection Biology which was also supported by AMP Therapeutics the IMAP Meeting is a further testament to the region's growing excellence in infectious diseases research."

About AMP Therapeutics (AMPT)

AMP Therapeutics was founded in 2009 as a spin-off from Prof. Ralf Hoffmann's laboratory at the University of Leipzig and is based in the Center for Biotechnology and Biomedicine at BIO CITY in Leipzig, Germany. First round investors in 2011 were the Boehringer Ingelheim Venture Fund and the Novartis Venture Fund. AMPT is engaged in the discovery and commercialization of new medicines for the treatment of severe bacterial infections predominantly caused by drug-resistant Gram-negative bacteria. Infections caused by drug-resistant pneumonia, bloodstream infections, surgical site infections and urinary tract infections represent a major global health threat with an unfavorable prognosis and are largely untreatable with existing antibiotics. AMPT addresses this significant unmet medical need by advancing the preclinical and clinical development of its proprietary antibacterial compounds. AMPT's technology is based on naturally occurring antimicrobial peptides found across various species.

www.amp-therapeutics.com

Contact: Dr. Marc W. Hentz, Managing Director AMP Therapeutics GmbH

info@amp-therapeutics.com